Literature DB >> 6299190

Effect of cyclosporin A on the production of interferon by human peripheral blood leukocytes in vitro.

J Abb, H Abb, F Deinhardt.   

Abstract

Cyclosporin A (CsA) was assessed for its effect on the production of antiviral activity by human peripheral blood leukocytes (PBL). CsA markedly reduced the production of interferon-gamma (IFN-gamma) in response to stimulation with lectin mitogens, bacterial products, alloantigens, or Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines (LCL). CsA-mediated suppression of IFN-gamma secretion was dose-dependent and did not result from a shift of kinetics of the production of antiviral activity. The production of IFN-alpha in response to stimulation with Corynebacterium parvum (CP), viruses, and synthetic polynucleotides was not affected by the addition of CsA. These findings confirm earlier observations that CsA predominantly acts on T lymphocyte function. CsA may prove a valuable agent to study the role of IFN-gamma in the pathogenesis of virus-associated malignant lymphoproliferative disease.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6299190     DOI: 10.1016/0166-3542(82)90006-7

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  3 in total

1.  Effects of cyclosporin A on humoral immune response and resistance against vesicular stomatitis virus in mice.

Authors:  S Charan; A W Huegin; A Cerny; H Hengartner; R M Zinkernagel
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

2.  Effects of cyclosporine A on ozone-induced pulmonary lesion formation: pharmacologic elimination of the T-lymphocyte regulatory response.

Authors:  M R Bleavins; N E Sargent; D Dziedzic
Journal:  Arch Environ Contam Toxicol       Date:  1995-02       Impact factor: 2.804

3.  Effect of cyclosporin A on immunity to Listeria monocytogenes.

Authors:  A W Hügin; A Cerny; M Wrann; H Hengartner; R M Zinkernagel
Journal:  Infect Immun       Date:  1986-04       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.